These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3185679)

  • 1. The place of angiotensin-converting enzyme inhibition in the treatment of cardiovascular diseases.
    Gavras H
    N Engl J Med; 1988 Dec; 319(23):1541-3. PubMed ID: 3185679
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiotensin-converting enzyme inhibitors for the prevention and treatment of cardiovascular disease.
    Frishman WH
    Heart Dis; 2000; 2(3):183-4. PubMed ID: 11794142
    [No Abstract]   [Full Text] [Related]  

  • 3. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril.
    Ferrari R
    Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):15-29. PubMed ID: 15723572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelin-converting enzyme inhibitors: their application in cardiovascular diseases.
    Cerdeira AS; Brás-Silva C; Leite-Moreira AF
    Rev Port Cardiol; 2008 Mar; 27(3):385-408. PubMed ID: 18551924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin converting enzyme inhibitor therapy.
    Róna G
    Ther Hung; 1991; 39(2):63-70. PubMed ID: 1948779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prospective trends in the study of the therapeutic action of angiotensin-converting enzyme inhibitors in cardiovascular diseases].
    Novikova LS; Arabidze GG
    Ter Arkh; 1990; 62(1):118-23. PubMed ID: 2159193
    [No Abstract]   [Full Text] [Related]  

  • 7. Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors.
    Weinberg MS; Weinberg AJ; Zappe DH
    J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):217-33. PubMed ID: 11881029
    [No Abstract]   [Full Text] [Related]  

  • 8. Angiotensin converting enzyme inhibitor-induced renal dysfunction: recommendations for prevention.
    Cooke HM; De Besse A
    Int J Clin Pharmacol Ther; 1994 Feb; 32(2):65-70. PubMed ID: 8004361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology.
    López-Sendón J; Swedberg K; McMurray J; Tamargo J; Maggioni AP; Dargie H; Tendera M; Waagstein F; Kjekshus J; Lechat P; Torp-Pedersen C;
    Eur Heart J; 2004 Aug; 25(16):1454-70. PubMed ID: 15302105
    [No Abstract]   [Full Text] [Related]  

  • 10. [Endothelium--a new target for a therapeutic action of angiotensin-converting enzyme inhibitors].
    Karpov IuA
    Ter Arkh; 2004; 76(6):94-6. PubMed ID: 15332589
    [No Abstract]   [Full Text] [Related]  

  • 11. Evolving role of angiotensin-converting enzyme inhibitors in cardiovascular therapy. Second International Symposium on Cilazapril. February 9 to 11, 1989, Basel, Switzerland. Proceedings.
    Am J Med; 1989 Dec; 87(6B):1S-99S. PubMed ID: 2532456
    [No Abstract]   [Full Text] [Related]  

  • 12. [Angiotensin receptor blocker often a valuable alternative to ACE inhibitors].
    Partanen J
    Duodecim; 2003; 119(13):1193-6. PubMed ID: 12908180
    [No Abstract]   [Full Text] [Related]  

  • 13. Prolongation of life with angiotensin converting enzyme inhibitor therapy.
    Torp-Pedersen C; Køber L
    Eur Heart J; 2000 Apr; 21(8):597-8. PubMed ID: 10731392
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of angiotensin converting enzyme inhibitors.
    Chatterjee K
    Heart Dis Stroke; 1992; 1(3):128-33. PubMed ID: 1344097
    [No Abstract]   [Full Text] [Related]  

  • 15. Introduction. The cardiovascular continuum in the 21st century: renin-angiotensin system blockade, the cardiovascular continuum in the 21st century.
    Probstfield JL; Weber MA
    Am J Cardiol; 2010 Jan; 105(1 Suppl):1A-2A. PubMed ID: 20102967
    [No Abstract]   [Full Text] [Related]  

  • 16. [The long way of angiotensin-converting enzyme inhibitors in the fight against cardiovascular diseases].
    Ferrari R; Ambrosio G; Chiariello M
    Ital Heart J; 2005 Nov; 6 Suppl 7():3S-4S. PubMed ID: 16485511
    [No Abstract]   [Full Text] [Related]  

  • 17. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RAAS inhibition/blockade in patients with cardiovascular disease: implications of recent large-scale randomised trials for clinical practice.
    Pitt B
    Heart; 2009 Aug; 95(15):1205-8. PubMed ID: 19401281
    [No Abstract]   [Full Text] [Related]  

  • 19. Angiotensin converting enzyme inhibition in cardiovascular risk populations: a practical approach to identify the patient who will benefit most.
    Asselbergs FW; van Gilst WH
    Curr Opin Cardiol; 2007 Jul; 22(4):267-72. PubMed ID: 17556876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of a new ACE inhibitor zofenopril (zocardis) in cardiovascular diseases].
    Ivleva AIa
    Ter Arkh; 2006; 78(8):89-93. PubMed ID: 17078226
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.